Informations générales (source: ClinicalTrials.gov)
Evaluation en Vie réelle de la qualité de Vie de Personnes Vivant Avec le VIH traité Par cabotégravir et Rilpivirine Par Patient-Reported Outcomes (PANTER)
Observational
University Paris 7 - Denis Diderot (Voir sur ClinicalTrials)
mai 2024
octobre 2026
26 avril 2025
Context The introduction of the long-acting injectable antiretroviral treatment
cabotegravir and rilpivirine into the therapeutic armamentarium for people living with
HIV represents a potentially significant evolution in patients' experience of their
treatment and pathology. Its effects on the quality of life of PLHIV are explored in this
research. In addition, the two-monthly intra-muscular injection regimen also raises
questions about the city-to-hospital transition of care for PLHIV, as well as compliance
with the therapeutic window.
Main objective To evaluate the effect of switching HIV treatment to CAB+RPV LA on
health-related quality of life on the "Treatment Impact" dimension of the PROQOL-HIV
questionnaire, 15 months after switching treatment.
Population People living with HIV-1 whose ARV treatment has been changed to an injectable
CAB+RPV LA treatment
Study Design Observational study. Inclusion at HIV medical follow-up visit for change of
ARV treatment to CAB/RPV.
Self-administered questionnaires at M3, M9 and M15 after change of treatment (first
CAB/RPV injection).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | DAVID ZUCMAN | 05/05/2025 07:12:15 | Contacter | ||
Critères
Tous
Inclusion Criteria:
- HIV-1 carriers
- Patients who changed treatment (as part of routine care) to injectable CAB+RPV at
the same visit as the inclusion visit
- HIV-RNA less than or equal to 50 copies/mL for at least 6 months prior to inclusion
visit
- Patient 18 years of age or older
- Patient able to read, understand and answer self-questionnaires in French
- HIV-1 carriers
- Patients who changed treatment (as part of routine care) to injectable CAB+RPV at
the same visit as the inclusion visit
- HIV-RNA less than or equal to 50 copies/mL for at least 6 months prior to inclusion
visit
- Patient 18 years of age or older
- Patient able to read, understand and answer self-questionnaires in French
- Pregnant or breast-feeding women
- Known hypersensitivity to cabotegravir or rilpivirine
- Documented resistance to cabotegravir or rilpivirine
- Chronically active hepatitis B (HBsAg+)
- Any pathology or history of treatment which, in the investigator's judgment, would
contraindicate the patient's inclusion in the study or prevent him/her from
following the constraints of the protocol.